MK-677 (Ibutamoren) - A Comprehensive Overview

Main ideas, concepts, and lessons

• What MK-677 (ibutamoren) is

  • An orally active compound being researched as a growth hormone secretagogue (GHS).
  • Acts as a ghrelin receptor agonist, which increases endogenous (natural) secretion of:
    • Growth hormone (GH)
    • IGF-1
  • Potentially designed to treat conditions like:
    • Growth hormone deficiencies
    • Sarcopenia (muscle loss with aging; pronunciation varies in subtitles)
    • Related conditions such as bone loss/osteoporosis, muscle wasting/catabolic states, and others mentioned in the video.

• Why oral dosing matters

  • The speaker emphasizes it’s bioavailable when swallowed, avoiding the need for injections like synthetic human GH.
  • Claims it has practical stability (longer shelf life; not needing refrigeration/freezing).

• General theme of effects supported by clinical studies (as presented)

  • Increases bone mineral density
  • Improves markers of bone formation
  • Raises IGF-1 and GH levels substantially
  • May increase fat-free mass and basal metabolic rate
  • Promotes nitrogen retention (anti-catabolic potential)
  • Improves sleep quality, particularly REM sleep
  • May influence immune function, hair growth, and other aging-related endpoints (often with caveats)

---

Effects and example clinical findings cited (non-exhaustive)

Bone and IGF-1 / bone turnover

• Postmenopausal osteoporotic women
  • 12-month study, 25 mg/day
  • Reported increase in bone mineral density
  • Reported as well tolerated
• Healthy obese men
  • 2-month randomized, double-blind, placebo-controlled
  • 24 men, ages 19–49
  • 25 mg/day
  • Increased bone formation markers within ~2 weeks
  • Increased serum osteocalcin by 2 months
• Elderly adults
  • 187 adults, ages 65+
  • 10–50 mg once daily for 2–9 weeks
  • Increased bone turnover in both healthy and impaired groups

Muscle / fat-free mass claims and measurement caveats

• Obese men (example)
  • 2 months, 25 mg/day
  • Claimed: ~3 kg lean mass gained vs placebo
  • Speaker caveat: much of “lean mass/fat-free mass gain” may be intracellular water and/or nitrogen retention, not purely true contractile muscle growth.
• Additional study example (ages 60–80)
  • ~1.6 kg increase in fat-free mass vs placebo
  • Presented as potentially offsetting age-related fat-free mass loss (anti-catabolic angle)

Anti-catabolic / nitrogen retention

• Calorie restriction experiment
  • 8 volunteers, ages 24–39
  • 18 kcal/kg/day for 2 periods of 14 days
  • Last 7 days: 25 mg MK-677/day vs placebo
  • Reported reversal of nitrogen wasting due to calorie deficit
  • Framed as possible support for chronic catabolic conditions if effects persist long-term

Sleep effects

• Young and older subjects
  • 8 young subjects (18–30)
  • 6 older subjects (65–71)
  • MK-677 increased REM sleep by up to ~50% (as stated)

Longevity / aging-related signaling (as framed)

• GH/IGF-1 restoration narrative
  • IGF-1 and GH levels rise toward “young adult” ranges
  • Speaker claims this could help prevent muscle/bone degradation in aging
• Hip fracture patients
  • ~84% increase in serum IGF-1 reported
• Telomere length
  • Higher IGF-1 associated with longer telomeres (presented as generally accepted in the video’s framing)
• Contradictory mortality note
  • Speaker acknowledges evidence is mixed/contradictory regarding long-term mortality and elevated IGF-1.

---

Immune, cancer, and other aging-related endpoints (as presented)

Immune system and cancer-related caveats

• Mouse study described
  • A growth hormone secretagogue shown to improve immune parameters and tumor resistance
  • Thymus deficiency reversal noted in mice (per subtitles)
• Cancer risk caution
  • Because IGF-1 promotes cellular proliferation, the speaker raises concern it could theoretically accelerate existing cancer growth.

Hair effects

• IGF-1’s role in hair follicle biology is discussed.
• Reported/claimed:
  • People with GH deficiency can have sparse hair
  • Some anecdotal improvement in hair growth/density
  • Speaker distinguishes this may not prevent androgenic alopecia specifically.

GH deficiency treatment angle

• Severely GH-deficient men (example)
  • 9 men, ages 17–34
  • Doses: 10 mg, 50 mg, or placebo
  • 10 mg
    • ~52% increase IGF-1
    • ~79% increase GH
  • 50 mg
    • ~79% increase IGF-1
    • ~82% increase GH
• Framed as potential alternative treatment concept for pediatric GH deficiency (with limitations).

---

Mechanism of action (as presented)

Physiologic pathway

• GH is secreted in pulses by the anterior pituitary.
• GH stimulates the liver to produce IGF-1, supporting:
  • linear growth
  • metabolic effects

How MK-677 is said to work

• MK-677 activates ghrelin receptors.
• This signals the pituitary to secrete GH.
• IGF-1 feedback prevents excessive GH production.

Correction of a misconception

• The speaker claims MK-677 does not increase the number of GH “events/pulses.”
• Instead, it increases the 24-hour GH production rate (stronger pulses, not more pulses).

Comparison mentioned

• Compared conceptually to GH-releasing peptides (subtitles name multiple peptides; one is described as most similar in ghrelin secretion effects).

---

Limitations and “where it may not work” (as presented)

• Likely ineffective when:
  • Hypothalamic-pituitary axis is non-functional (speaker’s phrasing)
  • Individuals who cannot secrete GH or don’t respond at all to MK-677
• Pediatric GH deficiency:
  • Speaker states ~30% of children may not normalize healthy GH/IGF-1 levels with MK-677 (as claimed in subtitles).

---

Dosing and dose-response claims (as presented)

• Diminishing returns
  • Above ~25 mg/day, additional GH/IGF-1 benefits are said to be smaller.
• Reported comparisons
  • No major GH difference between 10 mg vs 50 mg, but IGF-1 differed significantly.
• Summary comparison reiterated
  • 10 mg: IGF-1 +52%, GH +79%
  • 50 mg: IGF-1 +79%, GH +82%
• Tapering note
  • In a 12-month study, IGF-1 appears to peak early and then taper, leading the speaker to suggest a cyclical approach might be more beneficial (speaker framing).

---

Side effects and risks (as presented)

• Appetite increase
  • Speaker strongly emphasizes hunger increase due to ghrelin effects.
  • Framed as a major reason for recreational use and a barrier to dieting/cutting.
• Lethargy / fatigue (speaker personal emphasis)
• Intense dreams / vivid REM-associated dreams
• Water retention / edema and muscle pain
  • Muscle pain attributed to intracellular water and added stress.
• Blood pressure increases
  • Linked to edema.
• Glucose and insulin effects
  • Mixed clinical findings (some no change; some show increased fasting glucose / reduced insulin sensitivity).
  • Video highlights potential pathways to:
    • Insulin resistance
    • Type 2 diabetes risk in susceptible people
  • Mentions reactive hypoglycemia as a scenario involving exaggerated insulin response and subsequent glucose crashes.
• Cancer concern
  • Animal/immune benefits described, but IGF-1’s proliferative nature is cited as a theoretical risk for existing cancers.

---

Recreational / anecdotal use (as presented)

• Performance enhancement comparisons discussed:
  • Oral administration vs injections
  • Lower cost and convenience
  • Some report rapid “fat-free mass” gains early (likely water/nitrogen)
• Speaker’s personal report (anecdotal):
  • Rapid early “full” look from water/nitrogen retention (several pounds within a week)
  • Hunger makes cutting difficult (especially at lower body fat goals)
  • Hair density changes and improved hair growth anecdotes
  • Lethargy experienced and attempts to mitigate by timing
• Important stance: no endorsement for non-medical/recreational use.
  • Emphasizes the compound is not approved for general human use in the described context (per subtitle claims).

---

Supplement interaction discussed: huperzine A (as presented)

• Speaker claims huperzine A is used by some alongside MK-677 (“bro protocol” style).
• Theory described:
  • Higher HGH → body releases somatostatin to limit GH.
  • Huperzine A is suggested (hypothetically) to inhibit somatostatin, thereby increasing GH availability.
• Caveat:
  • Evidence described as weak, mechanism not strongly supported.
  • Speaker still personally uses it, noting it’s hard to measure its effect in this context.

---

“Insulin mimetic” add-on discussion (as presented)

• Speaker suggests some people consider insulin-related supplements if glucose regulation worsens.
• General logic:
  • If insulin sensitivity is impaired, nutrients are less efficiently used by muscle, increasing likelihood of storing calories as fat.
• Examples listed (as mentioned in subtitles; spellings unclear due to subtitle errors):
  • Berberine, cinnamon extract, alpha lipoic acid, fenugreek, Gymnema?, vin…, chromium, etc.
• Lifestyle basics also recommended:
  • Get leaner, reduce carbs, exercise/cardio.

---

Speakers or sources featured (as named in the subtitles)

• Derek (main speaker; referenced as “guys Derek” at the start)
• Lumis Pharma (company mentioned regarding acquiring licensing; described in video)
• Larger clinical trial context / study populations
  • Not named as specific institutions in subtitles
• Mice study
  • Source not specified beyond animal model
• More Plates More Dates
  • Referenced multiple times as the speaker’s article/website and platform (no individual named beyond Derek)